<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02021279</url>
  </required_header>
  <id_info>
    <org_study_id>ACL2012-001</org_study_id>
    <nct_id>NCT02021279</nct_id>
  </id_info>
  <brief_title>ACell MatriStem Pelvic Floor Matrix Versus Native Tissue Repair, Comparative Study</brief_title>
  <official_title>Evaluation of the Use of Transvaginal Resorbable Biologic Mesh as Compared to Traditional Non-Mesh Surgical Repair for Treating Pelvic Floor Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ACell Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ACell Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to assess the safety and effectiveness of MatriStem
      Pelvic Floor Matrix as compared to native tissue repair for the treatment of pelvic organ
      prolapse. Patients are evaluated throughout a 3 year follow-up period.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2014</start_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The safety and effectiveness of surgical success/failure.</measure>
    <time_frame>3 years</time_frame>
    <description>The composite outcome of surgical success evaluates anatomic outcome, patient reported outcome, and no retreatment pelvic organ prolapse.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The surgical success/failure based on an alternate definition of success.</measure>
    <time_frame>3 years</time_frame>
    <description>A composite outcome of surgical success based on an alternate definition of anatomic success, patient reported outcome, and no retreatment for pelvic organ prolapse.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">162</enrollment>
  <condition>Pelvic Organ Prolapse</condition>
  <arm_group>
    <arm_group_label>MatriStem Pelvic Floor Matrix</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>surgical mesh device</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Native Tissue Repair</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>suture repair</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MatriStem Pelvic Floor Matrix</intervention_name>
    <arm_group_label>MatriStem Pelvic Floor Matrix</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>native tissue repair</intervention_name>
    <arm_group_label>Native Tissue Repair</arm_group_label>
    <other_name>suture repair</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject's leading edge of POP is at or beyond the hymen. At or beyond the hymen is
             defined as POP-Q scores of Ba ≥ 0 or Bp ≥ 0 or C ≥ 0 (for prolapse of the apical
             compartment alone) or C ≥ -½ total vaginal length (for a multi-compartment prolapse
             that includes the apical compartment).

          -  Subject is seeking surgical intervention for symptomatic POP, which is defined as
             experiencing symptoms of vaginal bulging or pelvic heaviness. Vaginal bulge or pelvic
             heaviness will be considered present if a subject responds &quot;yes&quot; (≥1) to PFDI-20,
             question 3.

          -  Subject or subject's legally authorized representative is willing to provide written
             informed consent.

          -  Subject is willing and able to comply with the follow-up regimen.

        Exclusion Criteria:

          -  Subject has a known hypersensitivity to porcine-based materials (relevant to subjects
             in MatriStem Pelvic Floor Matrix Group only).

          -  Subject is pregnant or plans to become pregnant during the study.

          -  Subject has an active or chronic systemic infection including any gynecologic
             infection, urinary tract infection (UTI), or tissue necrosis.

          -  Subject has a known neurologic or medical condition affecting bladder function (e.g.
             multiple sclerosis, spinal cord injury, or stroke with residual neurologic deficit).

          -  Subject has chronic systemic pain syndrome (e.g. fibromyalgia, painful bladder
             syndrome).

          -  Subject has a systemic connective tissue disease (e.g., scleroderma, systemic lupus
             erythematous (SLE), Marfans syndrome, Ehlers Danhlos, collagenosis, polymyositis or
             polymyalgia rheumatica).

          -  Subject has uncontrolled diabetes mellitus (DM).

          -  Subject has a history of pelvic organ cancer (e.g. uterine, ovarian, bladder, or
             cervical).

          -  Subject has had prior or is currently undergoing radiation, laser therapy, or
             chemotherapy in the pelvic area.

          -  Subject has taken systemic steroids (within the last month), immunosuppressive or
             immunomodulatory treatment (within the last 3 months).

          -  Subject is seeking obliterative vaginal surgery as treatment for POP (colpoclesis).

          -  Subject is not able to conform to the modified dorsal lithotomy position.

          -  Subject is currently participating in or plans to participate in another device or
             drug study during this study.

          -  Subject is to planning to undergo concurrent surgical treatment of prolapse using mesh
             other than the MatriStem Pelvic Floor Matrix.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Melinda Wooten</last_name>
    <phone>443-283-2786</phone>
    <email>melindawooten@acell.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elizabeth Smith</last_name>
    <phone>443-283-2768</phone>
    <email>elizabethsmith@acell.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Stanford School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathryn Batham</last_name>
      <phone>650-724-7826</phone>
      <email>kbatham@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Eric Sokol, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic FLorida</name>
      <address>
        <city>Weston</city>
        <state>Florida</state>
        <zip>33331</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Mejia</last_name>
      <phone>954-659-5888</phone>
      <email>mejiagm@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Guillermo Davila, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Female Pelvic Medicine &amp; Urogynecology</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beth Rogers</last_name>
      <phone>616-588-1135</phone>
      <email>BRogers@grwh.org</email>
    </contact>
    <investigator>
      <last_name>Douglas M Van Drie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Premier Urology Group</name>
      <address>
        <city>Edison</city>
        <state>New Jersey</state>
        <zip>08837</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Haleema A Hameed</last_name>
      <phone>732-494-9400</phone>
      <phone_ext>1220</phone_ext>
      <email>hhameed@premierurologygroup.com</email>
    </contact>
    <investigator>
      <last_name>Neil Sherman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Atlantic Health System</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07960</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Pagnillo, RN, BSN</last_name>
      <phone>973-971-7267</phone>
      <email>Jennifer.Pagnillo@atlantichealth.org</email>
    </contact>
    <investigator>
      <last_name>Charbel Salamon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Princeton Urogynecology</name>
      <address>
        <city>Princeton</city>
        <state>New Jersey</state>
        <zip>08540</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alison Cooke, LPN</last_name>
      <phone>609-924-2230</phone>
      <email>acooke@princetonurogyn.com</email>
    </contact>
    <investigator>
      <last_name>Heather van Raalte, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Garden State Urology</name>
      <address>
        <city>Whippany</city>
        <state>New Jersey</state>
        <zip>07981</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Darlene Wendling</last_name>
      <phone>973-971-5373</phone>
      <email>Darlene.Wendling@atlantichealth.org</email>
    </contact>
    <investigator>
      <last_name>Michael Ingber, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Premier Medical Group of the Hudson Valley</name>
      <address>
        <city>Poughkeepsie</city>
        <state>New York</state>
        <zip>12601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren Passante</last_name>
      <phone>845-437-5002</phone>
      <email>lpassante@premiermedicalhv.com</email>
    </contact>
    <investigator>
      <last_name>Daniel Katz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Christ Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon Lamping</last_name>
      <phone>513-585-2166</phone>
      <email>sharon.lamping@thechristhospital.com</email>
    </contact>
    <investigator>
      <last_name>Mickey Karram, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ly Pung, RN</last_name>
      <phone>216-445-2494</phone>
      <email>PUNGL@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Marie Paraiso, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Burton, RN</last_name>
      <phone>405-271-1615</phone>
      <email>Kelly-Burton@ouhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Mikio Nihira, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Institute for Female Pelvic Medicine and Reconstructive Surgery</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcie Taff</last_name>
      <phone>610-435-9575</phone>
      <phone_ext>103</phone_ext>
      <email>mtaff@fpminstitute.com</email>
    </contact>
    <investigator>
      <last_name>Vincent Lucente, MD, MBA</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Center for Pelvic Health</name>
      <address>
        <city>Franklin</city>
        <state>Tennessee</state>
        <zip>37067</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Matthews</last_name>
      <phone>615-499-4740</phone>
      <email>lmatthews@associatesingastro.com</email>
    </contact>
    <investigator>
      <last_name>Barry Jarnagin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 20, 2013</study_first_submitted>
  <study_first_submitted_qc>December 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 27, 2013</study_first_posted>
  <last_update_submitted>October 21, 2016</last_update_submitted>
  <last_update_submitted_qc>October 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pelvic organ prolapse</keyword>
  <keyword>MatriStem</keyword>
  <keyword>pelvic floor matrix</keyword>
  <keyword>ACell</keyword>
  <keyword>native tissue repair</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prolapse</mesh_term>
    <mesh_term>Pelvic Organ Prolapse</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

